Japanese industrial conglomerate Asahi Kasei Corp. has announced its intention to acquire Swedish biotechnology firm Calliditas Therapeutics AB for approximately 11.8 billion kronor ($1.1 billion). This strategic move aims to bolster Asahi Kasei’s global presence in the healthcare sector.
The Japanese firm has offered 208 kronor per share, representing an 83% premium over Calliditas’ previous close. This announcement has led to a significant spike in Calliditas’ stock, which surged to a record 205.2 kronor in Stockholm trading following news of the acquisition.
With this purchase, Asahi Kasei is particularly keen on expanding its footprint in the pharmaceutical industry. Calliditas is known for its specialty in the treatment of rare diseases, and this acquisition brings with it Tarpeyo, a medication used to treat a form of chronic kidney disease. The drug has already secured multiple years of exclusivity in the U.S. market, making it a valuable addition to Asahi Kasei’s portfolio.
This move underscores a growing trend in the pharmaceutical industry, where companies are increasingly focusing on niche markets like rare diseases, which often come with exclusive marketing rights. For further details, you can access Bloomberg Law’s full coverage of the acquisition here.